• Lantern Pharma won Taiwan TFDA clearance to open Part 2 of its Phase 2 HARMONIC trial for LP-300 in EGFR L858R NSCLC.
• Local IRB clearance at the lead Taiwan site came Sept. 29, 2026, enabling patient screening and enrollment.
• Protocol amendment shifts to a single-arm study in never-smokers with L858R, extending LP-300 dosing to eight cycles from six.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lantern Pharma Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202610070831BIZWIRE_USPR_____20261007_BW674654) on October 07, 2026, and is solely responsible for the information contained therein.